DE602005011753D1 - Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration - Google Patents

Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration

Info

Publication number
DE602005011753D1
DE602005011753D1 DE602005011753T DE602005011753T DE602005011753D1 DE 602005011753 D1 DE602005011753 D1 DE 602005011753D1 DE 602005011753 T DE602005011753 T DE 602005011753T DE 602005011753 T DE602005011753 T DE 602005011753T DE 602005011753 D1 DE602005011753 D1 DE 602005011753D1
Authority
DE
Germany
Prior art keywords
midazolam
pharmaceutical compositions
high concentration
compositions
benzodiazapine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005011753T
Other languages
English (en)
Inventor
Franciscus Wilhelmus Merkus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE602005011753D1 publication Critical patent/DE602005011753D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
DE602005011753T 2004-01-14 2005-01-13 Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration Active DE602005011753D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0400804.1A GB0400804D0 (en) 2004-01-14 2004-01-14 Pharmaceutical compositions
PCT/EP2005/050133 WO2005067893A2 (en) 2004-01-14 2005-01-13 Pharmaceutical compositions comprising midazolam in a high concentration

Publications (1)

Publication Number Publication Date
DE602005011753D1 true DE602005011753D1 (de) 2009-01-29

Family

ID=31726180

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011753T Active DE602005011753D1 (de) 2004-01-14 2005-01-13 Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration

Country Status (23)

Country Link
US (2) US7700588B2 (de)
EP (1) EP1703896B1 (de)
JP (1) JP5085138B2 (de)
KR (1) KR20060130175A (de)
CN (1) CN1929816B (de)
AT (1) ATE417600T1 (de)
AU (1) AU2005205072B2 (de)
BR (1) BRPI0506868A (de)
CA (1) CA2553890C (de)
DE (1) DE602005011753D1 (de)
DK (1) DK1703896T3 (de)
EA (1) EA014096B1 (de)
ES (1) ES2319667T3 (de)
FI (2) FIC20230023I1 (de)
GB (1) GB0400804D0 (de)
IL (1) IL176774A0 (de)
MX (1) MXPA06008086A (de)
NO (3) NO336916B1 (de)
NZ (1) NZ548454A (de)
PL (1) PL1703896T3 (de)
PT (1) PT1703896E (de)
WO (1) WO2005067893A2 (de)
ZA (1) ZA200606310B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
NZ595196A (en) 2005-11-09 2013-03-28 Proteolix Inc Peptide-based compounds for enzyme inhibition
PL2041158T3 (pl) 2006-06-19 2013-08-30 Onyx Therapeutics Inc Peptydowe epoksyketony do hamowania proteasomu
ES2611995T3 (es) * 2007-01-19 2017-05-11 Hananja Ehf Métodos y composiciones para el suministro de un agente terapéutico
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2194965B1 (de) 2007-08-31 2016-07-20 Archimedes Development Limited Nichtwässrige pharmazeutische zusammensetzungen
US8507468B2 (en) * 2007-10-02 2013-08-13 Robert Orr Intranasal anti-convulsive compositions and methods
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
CN102309438B (zh) * 2010-07-02 2013-04-17 中国人民解放军军事医学科学院毒物药物研究所 一种咪达唑仑药物组合物及其用途
CN102335430B (zh) * 2010-07-14 2013-07-31 中国人民解放军军事医学科学院毒物药物研究所 包含咪达唑仑与神经保护剂的复方药物组合物
CN102462685B (zh) * 2010-11-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 一种咪达唑仑组合物、其制备方法及用途
ME02958B (de) 2011-05-13 2018-07-20 Euro Celtique Sa Intranasale pharmazeutische darreichungsformen mit naloxon
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US20200297734A1 (en) * 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US11045462B2 (en) 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
WO2019226753A1 (en) 2018-05-25 2019-11-28 Ucb Biopharma Sprl Benzodiazepine formulations
US20210379080A1 (en) 2018-12-18 2021-12-09 Cipla Limited Intranasal Formulation
US20210322343A1 (en) * 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders
CN113209013B (zh) * 2021-06-24 2023-04-07 新疆特丰药业股份有限公司 一种咪达唑仑液体制剂及其制备方法和用途
NL2031331B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of a short-acting psychedelic compound
NL2031332B1 (en) 2022-03-18 2023-09-29 Plethora Therapeutics B V Transmucosal delivery of psychoactive compounds

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3812853A (en) 1971-11-17 1974-05-28 P Crain Apparatus for applying medication or the like to human nasal passages
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
DE3767615D1 (de) 1986-03-10 1991-02-28 Kurt Burghart Pharmazeutikum sowie verfahren zu seiner herstellung.
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US4973596A (en) 1988-05-20 1990-11-27 Barr Laboratories, Inc. Method of administering a narcotic analgesic and dosage forms therefor
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DE69129110T2 (de) * 1990-05-10 1998-12-10 Bechgaard International Research And Development A/S, Hellerup Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
FR2662672B1 (fr) 1990-05-31 1992-08-21 Aerosols & Bouchage Dispensateur de melange.
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
ES2158910T3 (es) 1991-06-10 2001-09-16 Schering Corp Formulaciones en aerosol sin clorofluorocarbonos.
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
WO1994008552A2 (en) 1992-10-19 1994-04-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
CA2152684A1 (en) 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
US5529787A (en) 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
EP0704206B1 (de) 1994-09-30 2002-09-04 MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH Pharmazeutische Zusammensetzung
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US5948389A (en) 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
WO1998002187A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
DE19709702A1 (de) 1997-03-10 1998-09-17 Wolff Walsrode Ag Lackbindemittelzubereitungen, deren Herstellung und Verwendung
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
FR2772271B1 (fr) 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
CA2320772A1 (en) * 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
DE19807921A1 (de) 1998-02-25 1999-08-26 Pfeiffer Erich Gmbh & Co Kg Austrag-Steuerung für einen Medien-Spender
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1185246A1 (de) 1999-06-02 2002-03-13 Klöcker, Norbert, Dr.med. Pharmazeutische zusammmensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslischen wirkstoffen
RU2264209C2 (ru) 1999-07-26 2005-11-20 СК Корпорейшн Назальные противосудорожные композиции и способ введения противосудорожных агентов
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001030391A2 (en) 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040176359A1 (en) 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
NZ529417A (en) 2001-05-24 2006-11-30 Alexza Pharmaceuticals Inc Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
GB0116107D0 (en) 2001-06-30 2001-08-22 West Pharm Serv Drug Res Ltd Pharmaceutical composition
GB0130964D0 (en) 2001-12-24 2002-02-13 Special Products Ltd Pharmaceutical composition
US20060039869A1 (en) 2004-08-17 2006-02-23 Daniel Wermeling Intranasal delivery of antipsychotic drugs

Also Published As

Publication number Publication date
US20050153956A1 (en) 2005-07-14
DK1703896T3 (da) 2009-03-02
CN1929816B (zh) 2011-08-24
NO20063453L (no) 2006-09-26
KR20060130175A (ko) 2006-12-18
ATE417600T1 (de) 2009-01-15
NO336916B1 (no) 2015-11-23
GB0400804D0 (en) 2004-02-18
AU2005205072B2 (en) 2011-03-03
US20060009447A1 (en) 2006-01-12
PL1703896T3 (pl) 2009-06-30
ES2319667T3 (es) 2009-05-11
CA2553890C (en) 2012-10-02
EP1703896A2 (de) 2006-09-27
WO2005067893A3 (en) 2006-04-13
EA200601309A1 (ru) 2006-12-29
EA014096B1 (ru) 2010-08-30
ZA200606310B (en) 2007-12-27
WO2005067893A2 (en) 2005-07-28
PT1703896E (pt) 2009-02-25
JP5085138B2 (ja) 2012-11-28
CN1929816A (zh) 2007-03-14
IL176774A0 (en) 2006-10-31
AU2005205072A1 (en) 2005-07-28
EP1703896B1 (de) 2008-12-17
NZ548454A (en) 2010-05-28
CA2553890A1 (en) 2005-07-28
US7700588B2 (en) 2010-04-20
NO2023014I1 (no) 2023-03-21
NO2023011I1 (no) 2023-03-16
FIC20230023I1 (fi) 2023-07-11
MXPA06008086A (es) 2006-12-19
JP2007534660A (ja) 2007-11-29
BRPI0506868A (pt) 2007-05-29
FIC20230024I1 (fi) 2023-07-19

Similar Documents

Publication Publication Date Title
FIC20230024I1 (fi) Farmaseuttisia koostumuksia, jotka käsittävät midatsolaamia suuressa pitoisuudessa
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
EA200802204A1 (ru) Применение ингибиторов dpp iv
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
EA200701731A1 (ru) Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
CR20120019A (es) Composicion de insulina de accion prolongada
TW200744665A (en) Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
EA200702253A1 (ru) Фармацевтическая композиция
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
MA32588B1 (fr) Derives azotes de la pancratistatine
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
EA200800706A1 (ru) Способ приготовления кандесартана цилексетила
TR201104008T1 (tr) Bir antitümör ilacının oluşturulmasına ve stabilizasyonuna ilişkin yöntemler.
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
CU23529A1 (es) Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
TH128481A (th) 11-(2-ไพร์โรลิดิน-1-อิล-เอทอกซี)-14,19-ไดออกซา-5,7,26-ไตรอะซา-เตตราไซโคล [19.3.1.1(2,6).1(8,12)]เฮปทาโคซา-1(25),2(26),3,5,8,10,12(27),16,21,23-เดคาอีน ซิเตรท ซอลท์
이석원 Amygdala depotentiation and fear extinction

Legal Events

Date Code Title Description
8364 No opposition during term of opposition